Carlyle Group

The Carlyle Group is a global investment firm with over $300 billion in assets under management, specializing in private equity, credit, and real assets. While it is not itself a life sciences or healthcare company, it has invested more than $22 billion into the healthcare sector and has made significant investments and acquisitions across the biotech, pharma, CRO/CDMO, medtech, and health IT spaces. Notable recent activities include acquiring Abingworth to form Launch Therapeutics—a vehicle focused on funding late-stage clinical drug development—and majority stakes or growth investments in companies like Saama Technologies (AI-driven data analytics for drug development), Unchained Labs (life science tools for biologics/gene therapy), Inova Software (life sciences partnering platform), as well as portfolio holdings such as Soleno Therapeutics and Phathom Pharmaceuticals[1][2][3][5][6].